康華生物(300841.SZ):擬要求相關股東回購公司所持廣西愛寵股份
格隆匯5月8日丨康華生物(300841.SZ)公佈,截至公吿披露日,廣西愛寵生物科技有限公司(原名:廣西一曜生物科技有限公司,“廣西愛寵”)狂犬病滅活疫苗(PV/BHK-21株)尚未滿足上市銷售條件,根據公司與上海玉曜生物醫藥科技有限公司、上海一曜生物技術集團有限公司(原名:上海一曜生物技術(集團)有限公司,“一曜集團”)、莊賢韓及廣西愛寵於2020年6月28日簽署的《關於廣西一曜生物科技有限公司之股權轉讓協議》,公司有權要求上海玉曜生物醫藥科技有限公司、一曜集團、莊賢韓回購公司持有的廣西愛寵股份。
考慮到公司全資子公司康華動保(成都)生物科技有限公司(“康華動保”)已取得杭州佑本動物疫苗有限公司(“杭州佑本”)寵物狂犬病滅活疫苗在中國大陸及中國澳門、中國香港和中國台灣政府採購和寵物醫院線上線下全渠道的總經銷權,目前康華動保已開展寵物狂犬病滅活疫苗的銷售工作。為優化公司資產結構,集中優勢資源發展公司及子公司主營業務,公司擬要求相關股東回購公司持有的廣西愛寵股份。
公司於2022年5月8日召開的第二屆董事會第七次會議及第二屆監事會第六次會議審議通過了《關於出售股權退出關聯方共同投資企業暨關聯交易的議案》,公司與一曜集團、廣西愛寵就一曜集團回購公司持有的廣西愛寵股份達成一致,三方擬簽署《廣西愛寵生物科技有限公司股權回購協議》,一曜集團擬以32,492,273.97元回購公司持有的廣西愛寵8%股權(廣西愛寵於2021年5月完成增資,公司持股比例稀釋至8%),對應註冊資本375萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.